Parkwood LLC Kodiak Sciences Inc. Transaction History

Parkwood LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$1.8 - $7.49 $33,062 - $137,576	18,368 Added 168.71%	29,255 $53,000
Q2 2023 Aug 14, 2023	BUY	$4.3 - $9.48 $46,814 - $103,208	10,887 New	10,887 $75,000
Q1 2022 May 13, 2022	SELL	$7.09 - $89.45 $58,591 - $739,214	-8,264 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$80.85 - $128.49 $170,431 - $270,856	2,108 Added 34.24%	8,264 $701,000
Q3 2021 Nov 12, 2021	SELL	$81.97 - $106.94 $254,762 - $332,369	-3,108 Reduced 33.55%	6,156 $591,000
Q2 2021 Aug 13, 2021	BUY	$77.2 - $126.54 $22,696 - $37,202	294 Added 3.28%	9,264 $862,000
Q1 2021 May 14, 2021	BUY	$110.45 - $164.47 $415,292 - $618,407	3,760 Added 72.17%	8,970 $1.02 Million
Q4 2020 Feb 12, 2021	BUY	$60.78 - $154.03 $316,663 - $802,496	5,210 New	5,210 $765,000

39M

6.5K

5.8K

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $455M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

Get notified when there are updates to the investment portfolio of Parkwood LLC, based on Form 13F filings with the SEC.

Stay updated on Parkwood LLC with notifications on news.